Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Q3 Revenues, Income Rise

NEW YORK, Oct. 22 (GenomeWeb News) - Affymetrix reported revenues of $76.2 million for the third quarter today, up from $ 72.7 million for the same period last year.

These revenues included $71.1 million in product revenue, compared to $62.9 million for the third quarter of 2002.

The company’s net income rose with revenues, to $5.8 million for the quarter, compared to $0.6 million for the same period last year. This is the third consecutive quarter of profitability for the Santa Clara, Calif. microarray company.

For the quarter, R&D expenses remained nearly flat, at $16.5 million, compared to $16.7 million in the same period last year.

As of Sept. 30, Affymetrix had $50.4 million in cash and cash equivalents.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.